Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Iovance Biotherapeutics Inc (IOVA)  
$11.32 0.01 (0.09%) as of 4:30 Mon 4/22


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 213,871,000
Market Cap: 2.42(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $3.3 - $17.47
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 24.5
Insider 6 Months    : 24.5
Insider 3/6 Months : 49
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of of cell therapies as cancer immunotherapy products. Co.'s key product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition, Co. is investigating the effectiveness and safety of tumor infiltrating lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and peripheral blood lymphocyte therapy for treatment of chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 5,282,000 5,282,000 10,292,000 21,371,500
Total Buy Value $48,330,300 $48,330,300 $74,885,900 $147,000,736
Total People Bought 3 3 3 6
Total Buy Transactions 3 3 5 18
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-01-21 2023-10-20 2023-04-21 2022-04-21

   
Records found: 135
  Page 1 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2024-04-15 4 D $11.89 $16,967 D/D (1,427) 42,562     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2024-04-15 4 OE $0.00 $0 D/D 2,812 43,989     -
   Bilinsky Igor Chief Operating Officer   •       –      –    2024-04-15 4 D $11.89 $16,967 D/D (1,427) 38,026     -
   Bilinsky Igor Chief Operating Officer   •       –      –    2024-04-15 4 OE $0.00 $0 D/D 2,812 39,453     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2024-04-15 4 D $11.89 $105,238 D/D (8,851) 141,334     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2024-04-15 4 OE $0.00 $0 D/D 20,834 150,185     -
   Bilinsky Igor Chief Operating Officer   •       –      –    2024-03-04 4 D $16.96 $123,588 D/D (7,287) 36,641     -
   Bilinsky Igor Chief Operating Officer   •       –      –    2024-03-04 4 OE $0.00 $0 D/D 14,061 43,928     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2024-03-04 4 D $16.96 $136,579 D/D (8,053) 41,177     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2024-03-04 4 OE $0.00 $0 D/D 15,623 49,230     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2024-03-04 4 D $16.96 $194,175 D/D (11,449) 129,351     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2024-03-04 4 OE $0.00 $0 D/D 41,662 140,800     -
   Rothbaum Wayne P. Director   –       •      –    2024-02-20 4 B $9.15 $45,750,000 I/I 5,000,000 28,067,333 2.1 -6%     
   Dukes Iain D. Director   –       •      –    2024-02-20 4 B $9.15 $292,800 D/D 32,000 54,000 2.39 -6%     
   Mcpeak Merrill A Director   –       •      –    2024-02-20 4 B $9.15 $2,287,500 D/D 250,000 320,150 2.39 -6%     
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2024-01-16 4 D $8.37 $54,656 D/D (6,530) 99,138     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 20,834 105,668     -
   Bilinsky Igor Chief Operating Officer   •       –      –    2024-01-16 4 D $8.37 $13,199 D/D (1,577) 29,867     -
   Bilinsky Igor Chief Operating Officer   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 2,813 31,444     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2024-01-16 4 D $8.37 $13,199 D/D (1,577) 33,607     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2024-01-16 4 OE $0.00 $0 D/D 2,813 35,184     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2023-10-16 4 D $3.57 $4,980 D/D (1,395) 32,371     -
   Graf Finckenstein Friedrich Chief Medical Officer   •       –      –    2023-10-16 4 OE $0.00 $0 D/D 2,813 33,766     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2023-10-16 4 D $3.57 $31,598 D/D (8,851) 84,834     -
   Vogt Frederick G Interim CEO & General Counsel   •       –      –    2023-10-16 4 OE $0.00 $0 D/D 20,835 93,685     -
  135 Records found
  1  2  3  4  5  6   
  Page 1 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us